Drug Trial Radar · NCT06370273
Thromboprophylaxis in Lower Limb Immobilisation
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10,044
Planned (sponsor's estimate)
Start
Nov 12, 2024
Primary completion
Aug 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Queen Mary University of LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury. The main questions it aims to answer are: * whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care) * whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots. Participants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication. Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.
Conditions
- Thrombosis
- Injury Leg
Interventions
RivaroxabanDrug
10mg once daily via oral ingestion
ApixabanDrug
2.5mg twice daily via oral ingestion
Enoxaparin Injectable SolutionDrug
40mg once daily via subcutaneous injection
Tinzaparin Injectable SolutionDrug
4500 IU once daily via subcutaneous injection
Dalteparin Injectable SolutionDrug
5000 IU once daily via subcutaneous injection
Fondaparinux Injectable ProductDrug
2.5 mg once daily via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of net clinical benefit comprising clinical VTE event, major bleeding, and cause-specific mortalityTime frame: Within 90 days of randomisation
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Hull Teaching Hospitals NHS Trust
Hull, United Kingdom · Recruiting
Barts Health NHS Trust
London, United Kingdom · Recruiting
Kings College Hospital NHS Foundation Trust
London, United Kingdom · Recruiting
Northern Care Alliance NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Epsom and St Helier University Hospitals NHS Trust
Carshalton, Surrey, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.